Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 30;14(4):1482-1495.
doi: 10.21037/tlcr-24-866. Epub 2025 Apr 17.

Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review

Jia-Xin Lin  1 , Hao Sun  1 , Ying-Long Peng  1 , Zhi Xie  1 , Si-Yang Maggie Liu  1 , Yi-Long Wu  1
Affiliations
Review

Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review

Jia-Xin Lin et al. Transl Lung Cancer Res. .

Abstract

Background and objective: The mesenchymal-epithelial transition factor (MET) proto-oncogene plays an important role in the development of non-small cell lung cancer (NSCLC). MET tyrosine kinase inhibitors (TKIs) have shown promising antitumor activity in patients with NSCLC harboring MET alterations. Peripheral edema (PE), the most common adverse event of MET TKIs, has received increasing attention from clinicians. The aim of this review is to describe the incidence, potential molecular mechanisms, diagnosis, and management of MET TKI-induced PE, to increase the recognition and standardize the management of PE.

Methods: We conducted a comprehensive literature search across PubMed, Wanfang Med Online, China National Knowledge Infrastructure (CNKI), and the oncology conferences websites for related studies published between 2000 and 2023. Of the 491 titles screened, we identified 80 research articles fitting the inclusion criteria and a comprehensive literature review was conducted. The review incorporated patient conditions, comprehensive examinations, and clinical experiences to propose a standardized management framework.

Key content and findings: The review focused on the incidence of MET TKI-induced PE, its potential molecular mechanisms, diagnostic criteria, and management strategies. The etiology of edema is complex in cancer patients; however, it may involve treatment-related increases in vascular permeability, impacts on renal function, and hypoalbuminemia. Based on the literature review, a diagnostic and comprehensive management approach for MET TKI-induced PE is proposed, which includes prevention strategies, non-pharmacological treatments, pharmacological interventions, and dosage adjustments related to MET TKIs.

Conclusions: In this review, we propose a diagnostic and comprehensive management approach for MET TKI-induced PE. By standardizing management, clinicians can enhance patient care for those treated with MET TKIs, facilitating earlier detection of PE, reducing patient suffering, and improving treatment adherence and outcomes.

Keywords: MET tyrosine kinase inhibitor (MET TKI); Non-small cell lung cancer (NSCLC); adverse event (AE); peripheral edema (PE); safety management.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-866/coif). Y.L.W. reports the grants from AstraZeneca, BMS, and Pfizer and speaker fees from Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, MSD, Hengrui, Pfizer, and BMS. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Diagram of literature searches conducted in January 2024. AACR, American Association for Cancer Research; ASCO, American Society of Clinical Oncology; CSCO, Chinese Society of Clinical Oncology; CNKI, China National Knowledge Infrastructure; ESMO, European Society for Medical Oncology; WCLC, World Conference on Lung Cancer.
Figure 2
Figure 2
Comprehensive management of MET TKI-induced peripheral edema. Algorithm for the differential diagnosis (A) and clinical management of MET TKI-induced peripheral edema (B). CTCAE, Common Terminology Criteria for Adverse Events; DVT, deep venous thrombosis; MET, mesenchymal-epithelial transition factor; PE, peripheral edema; TKI, tyrosine kinase inhibitor.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Spitaleri G, Trillo Aliaga P, Attili I, et al. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target. Cancers (Basel) 2023;15:4779. 10.3390/cancers15194779 - DOI - PMC - PubMed
    1. Sakamoto M, Patil T. MET alterations in advanced non-small cell lung cancer. Lung Cancer 2023;178:254-68. 10.1016/j.lungcan.2023.02.018 - DOI - PubMed
    1. Nishio M, Kato T, Toyozawa R, et al. Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors. Target Oncol 2022;17:597-604. 10.1007/s11523-022-00912-y - DOI - PMC - PubMed
    1. Falchook GS, Kurzrock R, Amin HM, et al. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res 2020;26:1237-46. 10.1158/1078-0432.CCR-19-2860 - DOI - PubMed
    1. Mazieres J, Paik PK, Garassino MC, et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2023;9:1260-6. 10.1001/jamaoncol.2023.1962 - DOI - PMC - PubMed

LinkOut - more resources